{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:31:26Z","timestamp":1776353486244,"version":"3.51.2"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":1037,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1093\/annonc\/mdw544","type":"journal-article","created":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T14:19:40Z","timestamp":1476195580000},"page":"16-33","source":"Crossref","is-referenced-by-count":279,"title":["3rd ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)"],"prefix":"10.1016","volume":"28","author":[{"given":"F.","family":"Cardoso","sequence":"first","affiliation":[]},{"given":"A.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"E.","family":"Senkus","sequence":"additional","affiliation":[]},{"given":"M.","family":"Aapro","sequence":"additional","affiliation":[]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[]},{"given":"C.H.","family":"Barrios","sequence":"additional","affiliation":[]},{"given":"J.","family":"Bergh","sequence":"additional","affiliation":[]},{"given":"G.","family":"Bhattacharyya","sequence":"additional","affiliation":[]},{"given":"L.","family":"Biganzoli","sequence":"additional","affiliation":[]},{"given":"M.J.","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"L.","family":"Carey","sequence":"additional","affiliation":[]},{"given":"D.","family":"Corneliussen-James","sequence":"additional","affiliation":[]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[]},{"given":"V.","family":"Dieras","sequence":"additional","affiliation":[]},{"given":"N.","family":"El Saghir","sequence":"additional","affiliation":[]},{"given":"A.","family":"Eniu","sequence":"additional","affiliation":[]},{"given":"L.","family":"Fallowfield","sequence":"additional","affiliation":[]},{"given":"D.","family":"Fenech","sequence":"additional","affiliation":[]},{"given":"P.","family":"Francis","sequence":"additional","affiliation":[]},{"given":"K.","family":"Gelmon","sequence":"additional","affiliation":[]},{"given":"A.","family":"Gennari","sequence":"additional","affiliation":[]},{"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[]},{"given":"C.","family":"Hudis","sequence":"additional","affiliation":[]},{"given":"B.","family":"Kaufman","sequence":"additional","affiliation":[]},{"given":"I.","family":"Krop","sequence":"additional","affiliation":[]},{"given":"M.","family":"Mayer","sequence":"additional","affiliation":[]},{"given":"H.","family":"Meijer","sequence":"additional","affiliation":[]},{"given":"S.","family":"Mertz","sequence":"additional","affiliation":[]},{"given":"S.","family":"Ohno","sequence":"additional","affiliation":[]},{"given":"O.","family":"Pagani","sequence":"additional","affiliation":[]},{"given":"E.","family":"Papadopoulos","sequence":"additional","affiliation":[]},{"given":"F.","family":"Peccatori","sequence":"additional","affiliation":[]},{"given":"F.","family":"Penault-Llorca","sequence":"additional","affiliation":[]},{"given":"M.J.","family":"Piccart","sequence":"additional","affiliation":[]},{"given":"J.Y.","family":"Pierga","sequence":"additional","affiliation":[]},{"given":"H.","family":"Rugo","sequence":"additional","affiliation":[]},{"given":"L.","family":"Shockney","sequence":"additional","affiliation":[]},{"given":"G.","family":"Sledge","sequence":"additional","affiliation":[]},{"given":"S.","family":"Swain","sequence":"additional","affiliation":[]},{"given":"C.","family":"Thomssen","sequence":"additional","affiliation":[]},{"given":"A.","family":"Tutt","sequence":"additional","affiliation":[]},{"given":"D.","family":"Vorobiof","sequence":"additional","affiliation":[]},{"given":"B.","family":"Xu","sequence":"additional","affiliation":[]},{"given":"L.","family":"Norton","sequence":"additional","affiliation":[]},{"given":"E.","family":"Winer","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw544_bb0010","first-page":"489","article-title":"ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2)","volume":"23","author":"Cardoso","year":"2014","journal-title":"Simultaneous publication in The Breast"},{"key":"10.1093\/annonc\/mdw544_bb0015","unstructured":"Global Status of Advanced\/Metastatic Breast Cancer 2005\u20132015 Decade Report. www.breastcancervision.com and www.abc-lisbon.org (27 October 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdw544_bb0020","series-title":"November 2015 SEER data submission, posted to the SEER","article-title":"SEER Cancer Statistics Review, 1975\u20132013","author":"Howlader","year":"2016"},{"issue":"3","key":"10.1093\/annonc\/mdw544_bb0025","doi-asserted-by":"crossref","first-page":"191.","DOI":"10.1016\/S1359-6349(10)70474-2","article-title":"Trends in survival in metastatic breast","volume":"8","author":"Sundquist","year":"2010","journal-title":"Cancer Eur J Cancer"},{"key":"10.1093\/annonc\/mdw544_bb0030","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00595-015-1252-x","article-title":"Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer","volume":"46","author":"Kobayashi","year":"2016","journal-title":"Surg Today"},{"key":"10.1093\/annonc\/mdw544_bb0035","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cncr.22867","article-title":"The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer","volume":"110","author":"Chia","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw544_bb0040","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"10.1093\/annonc\/mdw544_bb0045","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1093\/annonc\/mdw544_bb0050","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0055","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdw544_bb0060","unstructured":"Key components of Patient Centered Care, adapted from Levit L et al. Delivering high-quality cancer care: charting a new course for a system in crisis. National Academy of Science: Institute of Medicine, The National Academies, 2013; 20,1. 3 p.3.4\u20133.7."},{"key":"10.1093\/annonc\/mdw544_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.breast.2016.04.004","article-title":"Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: results from the count us, know us, join us and here & now surveys","volume":"28","author":"Cardoso","year":"2016","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdw544_bb0070","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.ejca.2014.08.014","article-title":"Breast cancer during follow-up and progression \u2013 a population based cohort on new cancers and changed biology","volume":"50","author":"Karlsson","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw544_bb0075","doi-asserted-by":"crossref","first-page":"R92","DOI":"10.1186\/bcr2771","article-title":"Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)","volume":"12","author":"Thompson","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdw544_bb0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","article-title":"Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer","volume":"30","author":"Amir","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0085","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.breast.2012.12.004","article-title":"Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status","volume":"22","author":"Penault-Llorca","year":"2013","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdw544_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2016.116","article-title":"Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer","author":"Schrijver","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdw544_bb0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","article-title":"Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01\/UNICANCER)","volume":"15","author":"Andr\u00e9","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0100","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdw544_bb0105","article-title":"A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01)","volume":"34","author":"Soran","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamasurg.2015.4539","article-title":"Initial surgery and survival in stage IV breast cancer in the United States, 1988-2011","volume":"151","author":"Thomas","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1093\/annonc\/mdw544_bb0115","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","article-title":"Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer","volume":"14","author":"Greenberg","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0125","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw544_bb0130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"1","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdw544_bb0135","article-title":"Phase III, randomized study of trastuzumab emtansine (T-DM1) \u00b1 pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study","volume":"33","author":"Ellis","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1093\/annonc\/mdw544_bb0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.504","article-title":"PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) \u00b1 pertuzumab (P) for patients (pts) who progressed during\/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting","volume":"34","author":"Urruticoechea","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0145","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0150","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26\/breast international group 03-05 study","volume":"27","author":"von Minckwitz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0155","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/tbj.12284","article-title":"Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact","volume":"20","author":"Rayson","year":"2014","journal-title":"Breast J"},{"key":"10.1093\/annonc\/mdw544_bb0160","doi-asserted-by":"crossref","first-page":"307.","DOI":"10.1186\/1471-2407-14-307","article-title":"The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"14","author":"Tripathy","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdw544_bb0165","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study","volume":"29","author":"Andersson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0170","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","article-title":"Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study","volume":"110","author":"Burstein","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw544_bb0175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10549-016-3851-7","article-title":"Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study","volume":"158","author":"Smyth","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"15_suppl","key":"10.1093\/annonc\/mdw544_bb0180","doi-asserted-by":"crossref","first-page":"586.","DOI":"10.1200\/jco.2015.33.15_suppl.586","article-title":"The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis","volume":"33","author":"Andersson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/annonc\/mdv544","article-title":"In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium","volume":"27","author":"Lobbezoo","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdw544_bb0195","article-title":"PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+\/HER2\u2013 advanced breast cancer (ABC)","volume":"34","author":"Finn","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0200","first-page":"3472","article-title":"Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma","volume":"53","author":"Weigel","year":"1993","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw544_bb0205","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of estrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw544_bb0220","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0225","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0230","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clbc.2013.08.011","article-title":"Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2","volume":"13","author":"Pritchard","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdw544_bb0240","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"issue":"9 Suppl","key":"10.1093\/annonc\/mdw544_bb0245","first-page":"S3","article-title":"TNT: a randomized phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1\/2 breast cancer","volume":"75","author":"Tutt","year":"2015","journal-title":"Cancer Res"},{"issue":"Suppl. S3","key":"10.1093\/annonc\/mdw544_bb0250","article-title":"Overall survival (OS) from the phase 2 study of enzalutamide, an androgen receptor (AR) signaling inhibitor, in ar+ advanced triple-negative breast cancer (aTNBC)","volume":"51","author":"Cortes","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw544_bb0255","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdw067","article-title":"A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","volume":"27","author":"Bonnefoi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0260","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw544_bb0265","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0270","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrclinonc.2015.131","article-title":"Clinical overview of metronomic chemotherapy in breast cancer","volume":"12","author":"Munzone","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0275","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0280","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0285","article-title":"Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial","volume":"32: 5s","author":"Hortobagyi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0290","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.9501","article-title":"CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer","volume":"33","author":"Himelstein","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0295","doi-asserted-by":"crossref","unstructured":"VEJonesLLJensenKJMcIntyre. Evaluation of miracle mouthwash (MMW) plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: preliminary results of a randomized phase II study. 2015 San Antonio Breast Cancer Symposium; December 5\u20138, 2015; San Antonio, TX. Abstract P1-15-06.","DOI":"10.1158\/1538-7445.SABCS15-P1-15-06"},{"key":"10.1093\/annonc\/mdw544_bb0300","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2016.34.26_suppl.189","article-title":"Prevention of everolimus\/exemestane (EVE\/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): results of the SWISH trial","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1093\/annonc\/mdw544_bb0305","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"MASCC and ESMO Consensus Guidelines for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: ESMO clinical practice guidelines","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw544_bb0310","first-page":"CD008427.","article-title":"Interventions for fatigue and weight loss in adults with advanced progressive illness","volume":"1","author":"Payne","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdw544_bb0315","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3322\/caac.21268","article-title":"Screening, evaluation and management of cancer-related fatigue: ready for implementation to practice","volume":"65","author":"Berger","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdw544_bb0320","article-title":"A practical approach to fatigue management in colorectal cancer","author":"Aapro","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1093\/annonc\/mdw544_bb0325","doi-asserted-by":"crossref","first-page":"121.","DOI":"10.1186\/s12916-015-0362-z","article-title":"Effects of an 18-week exercise programme started early during breast cancer treatment: a randomized controlled trial","volume":"8","author":"Travier","year":"2015","journal-title":"BMC Med"},{"key":"10.1093\/annonc\/mdw544_bb0330","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ctrv.2014.01.004","article-title":"Management of fatigue in patients with cancer \u2013 a practical overview","volume":"40","author":"Koornstra","year":"2014","journal-title":"Cancer Treat Rev"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419319337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419319337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/1\/16\/11013301\/mdw544.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:05:47Z","timestamp":1624694747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419319337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0923753419319337"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw544","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}